DUBLIN, Aug. 17, 2023 /PRNewswire/ — The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 17, 2023, approved an increase in the company’s cash dividend for the second quarter of fiscal year 2024 versus the prior year, raising the quarterly amount to $0.69 per ordinary share. This quarterly declaration is consistent with the first […]
Other News
HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio
Southlake, TX, Aug. 17, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announces that it has been issued a notice of patent […]
Silence Therapeutics Reports Second Quarter 2023 Results
LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights. “Silence’s strong second quarter […]
Heart & Rhythm Institute of Trinity and Avertix Announce Partnership to Improve Cardiac Care and Patient Monitoring
EATONTOWN, N.J. and TRINITY, Fla., Aug. 16, 2023 (GLOBE NEWSWIRE) — Avertix Medical, Inc. (“Avertix” or the “Company”), a company focused on improving long-term management and outcomes of high-risk coronary disease in patients who have survived one or more heart attacks, and the Heart & Rhythm Institute of Trinity, an ambulatory surgery […]
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
BOSTON, Aug. 16, 2023 (GLOBE NEWSWIRE) — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company dedicated to developing innovative therapies designed to improve patient symptoms and function by enhancing cellular energetics, today announced that it has completed enrollment in the IMPROVE-ISCHEMIA Phase 2 placebo-controlled clinical trial of the investigational therapy, […]
Heart Failure start-up, Acorai, embarks on the next vital stage towards regulatory approval
HELSINGBORG, Sweden, Aug. 16, 2023 /PRNewswire/ – Today, Acorai, a start-up medical device manufacturer from Sweden, has announced the initiation of a global clinical trial with the enrollment of its first patient in London, UK. Acorai was designated as a breakthrough device by the US FDA in August 2023 and they aim to submit their heart monitor […]
Instylla Announces Completion of $30MM EQUITY Financing
BEDFORD, Mass., Aug. 15, 2023 /PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the closing of a $30 million financing round. This financing round was led by new investor, Delos Capital, with continued participation from the investor syndicate of Excelestar Ventures, Ascension Ventures, Catalyst Health […]
MedAlliance announces the completion of enrollment in SAVE Trial with SELUTION SLR for Treatment of AV Fistulas in Renal Dialysis Patients
GENEVA, Aug. 15, 2023 /PRNewswire/ — MedAlliance has announced completion of patient enrollment in the SAVE Clinical Trial with the SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of failed AVF (arteriovenous fistulas) in renal dialysis patients. SELUTION SLR is a novel sirolimus-eluting balloon that provides a controlled sustained release of […]
Clario and AliveCor collaborate to offer advanced, trial-focused six-lead ECG solutions for monitoring in decentralized clinical trials
PHILADELPHIA, Aug. 15, 2023 /PRNewswire/ — Clario, a healthcare research technology company that delivers leading endpoint technology solutions for clinical trials, today announced an expansion to its collaboration with AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology. This collaboration will enable trial participants to collect medical-grade six-lead ECG readings in the comfort […]
CathVision Secures FDA Clearance of First & Only EP Recording System with AI Algorithm to Measure Success of Cardiac Ablation
COPENHAGEN, Denmark, Aug. 15, 2023 /PRNewswire/ — CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the FDA clearance and commercial availability of the PVI AnalyzerTM and Signal ComplexityTM algorithms. These algorithms are part of the CARDIALYTICSTM suite of artificial intelligence-powered analytics integrated into […]
Recent
Accelerating Adoption of AI Reporting in Radiology Has Propelled Replacement of Legacy SR Integration Technology
FDA Grants Coredio Breakthrough Designation for AI Platform Bringing Advanced Heart Failure Assessment Beyond the Hospital
BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure
Popular
- No commented posts yet